NEW YORK, Dec 19 - Oxford GlycoSciences has extended a proteomics agreement with Pfizer to discover protein biomarkers and potential drug targets for Alzheimer’s disease and atherosclerosis, OGS announced Tuesday.

The new agreement continues a joint research collaboration the two companies began in April 1998 for another two years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.